Investigational drug · Phase 3
Lasofoxifene
Also called: AZU-101
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
9
Any phase or sponsor naming "Lasofoxifene"
First trial start
2019
Sep 20, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lasofoxifene", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Vulvo Vaginal Atrophy (VVA)
- Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Lasofoxifene" as an intervention, largest first.
- Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)Pivotal-lookingCompleted
Ligand PharmaceuticalsIndustry
NCT00141323 · 8,556 participants (planned) · Start Nov 2001 · Primary completion Dec 2007
Drug: lasofoxifene; lasofoxifene · For: Osteoporosis
Sites: Birmingham, Alabama; La Jolla, California; Palm Desert, California · 201 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPivotal-lookingRecruiting
LeonaBioIndustry
NCT05696626 · 600 participants (planned) · Start Oct 31, 2023 · Primary completion Apr 2027
Drug: Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib · For: Metastatic Breast Cancer
Sites: Scottsdale, Arizona; Tucson, Arizona; Santa Rosa, California · 224 sites in all
- Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone LossPivotal-lookingCompleted
Ligand PharmaceuticalsIndustry
NCT00163137 · 540 participants · Start May 2003 · Primary completion Oct 2005
Drug: lasofoxifene; raloxifene and 1 more · For: Osteoporosis
Sites: Albany, California; Berkeley, California; La Jolla, California · 72 sites in all
- Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose EvaluationPivotal-lookingCompleted
Ligand PharmaceuticalsIndustry
NCT00143273 · 497 participants · Start Jun 2004 · Primary completion Mar 2006
Drug: lasofoxifene; Placebo and 2 more · For: Osteoporosis
Sites: Fukuoka, Japan; Kagoshima, Japan; Miyazaki, Japan · 17 sites in all
- Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPivotal-lookingCompleted
Sermonix Pharmaceuticals Inc.Industry
NCT03781063 · 100 participants · Start Sep 20, 2019 · Primary completion May 8, 2025
Drug: Lasofoxifene; Fulvestrant · For: Locally Advanced or Metastatic Breast Cancer
Sites: Phoenix, Arizona; Yuma, Arizona; Duarte, California · 51 sites in all
Azure Biotech Inc.Industry
NCT06197568 · 90 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2026
Drug: Lasofoxifene Tartrate · For: Vulvo Vaginal Atrophy (VVA)
Sites: Saint Paul, Minnesota
Ligand PharmaceuticalsIndustry
NCT00674453 · 51 participants · Start Sep 2004
Drug: Lasofoxifene · For: Bone Loss
Sites: Sheffield, United Kingdom
Sermonix Pharmaceuticals Inc.Industry
NCT04432454 · 29 participants · Start Sep 29, 2020 · Primary completion Jan 28, 2025
Drug: Lasofoxifene and abemaciclib (VERZENIO (R)). · For: Metastatic Breast Cancer
Sites: Birmingham, Alabama; Yuma, Arizona; Fountain Valley, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- In silico investigations of inhibition capabilities of selective estrogen receptor modulators against estrogen receptor - α (ER-α) in breast cancer.
Dey C, Singh PP, Chinyoti K, et al. · J Mol Graph Model 2026
- Vepdegestrant (ARV-471): pharmacokinetics, drug metabolism and clinical translation of an oral ERα-targeting PROTAC.
Rana N, Patel A · Expert Opin Drug Metab Toxicol 2026
- Breaking New Ground in Oncology: FDA Acceptance of Vepdegestrant NDA Marks a Milestone for PROTAC Therapies in Breast Cancer.
Zhang J · Curr Med Chem 2026
- The rise of selective estrogen receptor modulators (SERMs) in breast cancer therapy: a promising horizon.
Al-Zoubi RM, Garada K, Zarour AA, et al. · Cancer Treat Res Commun 2026
- Comparison of estrogens and selective estrogen receptor modulators (SERMs) used for menopausal hormone therapy.
Stanczyk FZ, Yang JL, Coelingh Bennink HJT, et al. · Menopause 2025
- PARP-1 as a novel target in endocrine-resistant breast cancer.
Zicarelli A, Talia M, Lainé M, et al. · J Exp Clin Cancer Res 2025
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
- TQB3616Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.